Group 1 - Precigen Inc. (NASDAQ:PGEN) is recognized as a promising multibagger stock, particularly due to its UltraCAR-T platform which aims for faster manufacturing and improved safety profiles in CAR-T treatments [1] - The company's stock has surged over 300% year-to-date, with a notable doubling of share price since mid-August following the FDA approval of its Papzimeos therapy, the first approved treatment for adults with recurrent respiratory papillomatosis [2] - Analysts have reacted positively to the FDA approval, with JPMorgan upgrading the stock to Neutral from Underweight, and Cantor Fitzgerald and H.C. Wainwright reaffirming their Buy ratings [3] Group 2 - The FDA approval of Papzimeos is seen as favorable, covering a broad indication for approximately 27,000 U.S. adults, with projected sales of $15 million by Q4 2025 [4] - Precigen focuses on developing gene and cellular therapies, particularly in the fields of immuno-oncology, autoimmune disorders, and infectious diseases [5]